OxfordBioMedica

World-leading Expertise in Gene and Cell Therapy

Annual General Meeting
7 May 2015

Forward-looking statements

OxfordBioMedica

This presentation does not constitute an offer to sell or a solicitation of offers to buy Ordinary Shares (the "Securities"). Although reasonable care has been taken to ensure that the facts stated in this presentation are accurate and that the opinions expressed are fair and reasonable, the contents of this presentation have not been formally verified by Oxford BioMedica plc (the "Company") or any other person. Accordingly, no representation or warranty, expressed or implied, is made as to the fairness, accuracy, completeness or correctness of the information and opinions contained in this presentation, and no reliance should be placed on such information or opinions. Further, the information in this presentation is not complete and may be changed. Neither the Company nor any of its respective members, directors, officers or employees nor any other person accepts any liability whatsoever for any loss howsoever arising from any use of such information or opinions or otherwise arising in connection with this presentation.

This presentation may contain forward-looking statements that reflect the Company's current expectations regarding future events, its liquidity and results of operations and its future working capital requirements. Forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the success of the Company's development strategies, the successful and timely completion of clinical studies, securing satisfactory licensing agreements for products, the ability of the Company to obtain additional financing for its operations and the market conditions affecting the availability and terms of such financing.

Overview

- Oxford BioMedica is a world-leading gene & cell therapy business
- Proprietary technologies
  - Gene delivery platform based on lentiviral vector IP
  - 5T4 antigen/antibody in immunotherapy
- Pipeline of clinical and early product development candidates
- OXB Solutions business generating revenues
- Unique IP and technical capabilities validated by
  - Lentiviral vector IP – Novartis (CAR-T programmes), GSK
  - Product licences – Sanofi (StarGen™/UshStat®)
  - Process development – Novartis, ImmuneDesign
- Well-financed and potential to generate cash by 2017

2014/2015 key achievements

OxfordBioMedica

- ✓ Proprietary pipeline advanced with four clinical programmes in development and two other products being prepared for Phase I/II
  - ✓ RetinoStat® recruitment completed in Phase I trial which will report in 2015
  - ✓ New CART-5T4 programme initiated in-house, combining both OXB's LentiVector® and 5T4 technology platforms
  - ✓ £2.2 million grant received from Innovate UK to fund a Phase I/II clinical trial of OXB-102 in Parkinson's disease commencing early 2016
  - ✓ Sanofi granted global rights to StarGen™ and UshStat® across all ocular indications
- ✓ IP, technology and manufacturing capability validated by major new licensing and manufacturing contract with Novartis
  - ✓ Agreement worth up to $90 million over the next three years including licensing royalties when CTL019 is commercialised
- ✓ Revenue increased through licensing, up front partner payments, manufacturing and R&D collaborations
- ✓ Cash position strengthened through £20m equity fundraise (June 2014) and $50m loan facility (May 2015)

Oxford BioMedica's business model



Product Update

Portfolio of pipeline assets (excluding those already out-licensed)

OxfordBioMedica

	Product	Indication	Stage	Next inflection	Est. date
Lentiviral vector TECHNOLOGY					
OPHTHALMOLOGY	RetinoStat®	Wet AMD	Phase I follow up stage (primary end point met)	Phase I CSR	2015
	EncorStat®	Corneal graft rejection	Phase I/II preparation	FPI Phase I/II	2016
	Glaucoma-GT	Chronic glaucoma	Pre-clinical	End pre-clinical	2016
CNS	ProSavin® *OXB-102*	Parkinson's disease	Phase I/II complete Phase I/II preparation	FPI Phase I/II	2016
	MoNuDin®	Motor neuron disease	Research	End pre-clinical	2015/16
NEW IDEAS	Investigating several therapy areas where Lenti based vectors have an advantage over AAV due to payload capacity			TBD	TBD
	Exploring possibilities to enter cell therapy field in our own right – e.g. CAR-T 5T4				
5T4 TECHNOLOGY					
ONCOLOGY	TroVax®	Cancer (multiple)	Phase II ongoing	End Phase II	2015/16
	CAR-T 5T4	Cancer (multiple)	Pre-clinical	End pre-clinical	2016

Product news

- Retinostat
  - Phase I results
    - Safe and well-tolerated
    - Signs of clinical benefit – visual acuity stabilisation and reduction in vascular leakage
  - Next steps
    - In-depth discussion with Principal Investigators and Key Opinion Leaders
    - Determine optimal indication(s) and pathway for future development



- ProSavin
  - 3 year follow up data
    - Indicates that the improvement in motor function seen at 6 and 12 months has been sustained in majority of patients for up to 3 years



Product news

- OXB-102 and Encorstat
  - Phase I/II studies expected to start in H1 2016
  - Both partially funded by Innovate UK grants

- TroVax
  - Three investigator-led open label Phase II studies in progress
    - Mesothelioma, colorectal cancer, ovarian cancer
  - Results expected from at least one study in 2015

- CAR-T 5T4
  - A gene modified autologous T cell engineered with lentiviral vector to express an antibody against 5T4; delivered by IV infusion
  - Acts by re-directing a patient's T cells to recognise the 5T4 tumour antigen and kill the cell expressing it
  - Pre-clinical results due 2016



Novartis contract

Novartis contract (October 2014)

- Initial contract May 2013 – proved our capabilities
- Non-exclusive licence to OXB's lentiviral vector platform IP in oncology
- Process development collaboration
  - Arising IP owned by OXB
  - NVS have exclusive licence to arising IP in CAR-T cell products
- Initial 3 year manufacturing contract for clinical supply for NVS CTL019 programme – potential to extend
- Financial terms include
  - $4.3m equity investment
  - IP licence
    - $9.7m non-refundable upfronts
    - Undisclosed royalties on CTL019 and other CAR-T products
  - Manufacturing and process development
    - Up to $76m over 3 years



Acquisition of Windrush Court

OxfordBioMedica

- Windrush Court office and laboratory facilities
  - Completed purchase (announced 13 October 2014; £3.2 million)
  - Refurbishment underway
  - Headquarters office building with fully fitted laboratories on secure site. 6,684 m^2 (71,955 sq ft)
  - Consolidates entire activities in Oxford, improving operational effectiveness, and will also provide additional capacity to accommodate the planned growth in business

Medawar Centre

Windrush Court

OXB facilities

Windrush Court
Corporate Headquarters & Laboratories
71,955 sq. ft (6,684 sq m)
(under reconfiguration)

GMP Warehouse Hub
2,691 sq.ft (250 sq. m)
Material transfer/ temperature controlled / monitored storage

Medawar Centre
The Oxford Science Park
28, 000 sq. ft (2,610 sq. m)
GLP/GMP/GCP Laboratories
GMP QC analytics/ release/stability testing
Clinical/non-clinical analysis
Analytical development
Product/Process development

Yarnton (GMP4)
18,300 sq. ft (1,700 sq. m)
API manufacturing facility
(under construction)

Harrow House (GMP1/GMP2/GMP3)
Fill & Finish & Chancery Gate)
32,000 sq.ft (2,980 sq.m)
API manufacturing facility
(under reconfiguration)
GMP QC microbiology laboratories
Raw material testing
GMP cold chain warehouse & office space

Transport Way facilities

OxfordBioMedica



Yarnton facility

OxfordBioMedica

Future manufacturing capacity

OxfordBioMedica



Clean room capacity

- Current (GMP1) = 390 sq.m,
- Future state (4Q,2016) = 2,245 sq.m

Financial position

- Cash at end 2014 – £14m
- $50m loan facility secured May 2015
  - $25m drawn down
  - £3m AMSCI loan repaid and facility terminated
- Capital expenditure across 2015/2016 expected to be in the region of £20m
- Manufacturing and process development revenues set to grow in 2015, reducing underlying operational cash burn

Upcoming potential value driving news flow

OxfordBioMedica

2015	Further IP licences/manufacturing/process development contracts RetinoStat® decision regarding Phase II indication and development pathway Identification of new product development candidates TroVax® Phase II studies – initial results
2016	MoNuDin® pre-clinical results FPI OXB-102 clinical programme FPI EncorStat® clinical programme StarGen™/UshStat® development milestones Glaucoma-GT pre-clinical results CAR-T 5T4 pre-clinical results

PLUS - updates from Novartis on CTL019 programme from time to time

Summary

- Lentiviral vector IP recognised by Novartis, GSK
- Internal clinical programmes
  - Three gene therapy product candidates in Phase I/II development
  - Three investigator-led Phase II TroVax® studies
- Out-licensed clinical programmes
  - Two ophthalmology *in vivo* Phase I/II products licensed to Sanofi
  - Two out-licensed 5T4 antibody technology phase I studies
- Further potential product development opportunities being evaluated
  - Including CAR-T 5T4
- Significant revenue potential from manufacturing and process development

Contact us

Oxford BioMedica plc
Windrush Court
Transport Way
Oxford
OX4 6LT

John Dawson, CEO
Tim Watts, CFO

www.oxfordbiomedica.co.uk
enquiries@oxfordbiomedica.co.uk

Tel: +44 (0) 1865 783 000